Wednesday, August 10, 2016 4:46:11 AM
I have reviewed several emails where NNVC claimed that the agreement with Theracour was strictly to prevent a hostile takeover and to protect the intellectual property. If that were the case then what is the 15 percent royalty for? Let alone the 30 percent markup on everything that Theracour bills to NNVC (including salaries). With respect to the 30 percent markup, have you read the financial statements since NNVC purchased the building from Theracour? Theracour is billing NNVC for each and every salary and there is not one mention of what NNVC is getting from Theracour to use it's facility and equipment.
Now why would anyone pay out 10 million dollars for a facility and equipment and let another company come in and use it free of charge and then pay that company and it's employees (plus 30 percent I might add)?
You appear to have invested in this company and it is curious to me as to why you do not ask any direct questions about any of this? Why would you not ask them to send you proof that they have been in contact with any Big Pharma companies. I would bet that question gets deflected, most likely because it is simply not true. Why don't you ask when they expect 200g of herpecide to be shipped? How about when will the facility be cGMP compliant? Ask for proof that they have even applied? You will get nothing back from NNVC.
All in all, I could go on forever pointing out the total gibberish in the companies recent filing which I suspect will all come to light in several months when the company has yet another excuse as to why nothing has been delivered (Herpecide should have been delivered months ago). There is a reason Big Pharma is not interested, for the reasons above and many other reasons, NNVC is worthless. Always has been. "
A very insightful and prescient analysis I found posted elsewhere on the internet, from about one year ago.
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM